Lineage Cell Therapeutics (XTAE:LCTX) Insider Ownership : 0.00 % (As of May. 17, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lineage Cell Therapeutics's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lineage Cell Therapeutics's Institutional Ownership is 14.85%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lineage Cell Therapeutics's Float Percentage Of Total Shares Outstanding is 74.13%.

Lineage Cell Therapeutics Insider Ownership Historical Data

The historical data trend for Lineage Cell Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Insider Ownership Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Insider Ownership

Get a 7-Day Free Trial

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Insider Ownership	Get a 7-Day Free Trial															-	-	-	-	-

Lineage Cell Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.